Newfeed

Concurrent publication in the journal Cancer Discovery highlights NST-628’s differentiated mechanism and preclinical activity across diverse KRAS-, NRAS-, and BRAF-driven tumors Phase 1 study of NST-628 open and enrolling patients with advanced solid tumors; Company expects to initiate dosing

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: